FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
BOSTON and MIAMI, Oct. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102 for the treatment of patients with dyst... Biopharmaceuticals, Dermatology, FDA Aegle Therapeutics, Dystrophic Epidermolysis Bullosa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Dermatology | Epidermolysis Bullosa | Food and Drug Administration (FDA) | Grants | Marketing | Pharmaceuticals | Skin